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Background: Genetic risk scores have been developed for coronary artery disease and atherosclerosis, but are not
predictive of adverse cardiovascular events. We asked whether peripheral blood expression profiles may be
predictive of acute myocardial infarction (AMI) and/or cardiovascular death.
Methods: Peripheral blood samples from 338 subjects aged 62 ± 11 years with coronary artery disease (CAD) were
analyzed in two phases (discovery N = 175, and replication N = 163), and followed for a mean 2.4 years for
cardiovascular death. Gene expression was measured on Illumina HT-12 microarrays with two different
normalization procedures to control technical and biological covariates. Whole genome genotyping was used to
support comparative genome-wide association studies of gene expression. Analysis of variance was combined with
receiver operating curve and survival analysis to define a transcriptional signature of cardiovascular death.
Results: In both phases, there was significant differential expression between healthy and AMI groups with overall
down-regulation of genes involved in T-lymphocyte signaling and up-regulation of inflammatory genes. Expression
quantitative trait loci analysis provided evidence for altered local genetic regulation of transcript abundance in
AMI samples. On follow-up there were 31 cardiovascular deaths. A principal component (PC1) score capturing
covariance of 238 genes that were differentially expressed between deceased and survivors in the discovery phase
significantly predicted risk of cardiovascular death in the replication and combined samples (hazard ratio = 8.5,
P < 0.0001) and improved the C-statistic (area under the curve 0.82 to 0.91, P = 0.03) after adjustment for traditional
covariates.
Conclusions: A specific blood gene expression profile is associated with a significant risk of death in Caucasian
subjects with CAD. This comprises a subset of transcripts that are also altered in expression during acute myocardial
infarction.Background
Coronary artery disease (CAD) is a complex multifactor-
ial disease resulting from the interplay between genetic,
environmental, and behavioral factors. The promise of
genetic research in CAD includes development of
unique genomic risk scores to enhance risk prediction
and discovery of novel therapeutic targets [1-3]. Al-
though genome-wide association studies have identified* Correspondence: greg.gibson@biology.gatech.edu
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unless otherwise stated.numerous SNPs that associate with CAD [4-7], as with
most complex traits, the discovered variants explain only
a small fraction of risk [8]. Recent advances in gene ex-
pression analysis have also discovered transcriptomic
signatures in peripheral blood that associate with pres-
ence and severity of CAD as well as risk of adverse
events, possibly in a sex-specific manner [9,10].
Numerous studies have combined SNPs identified in
genome-wide association studies to generate risk scores
for CAD, in some cases generating marginal improve-
ment on traditional risk models [1,11,12]. There is also a
pressing need for biomarkers of risk of cardiac events
within the incident CAD patient population. One small. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gene expression signature associated with acute myocar-
dial infarction (AMI) that persisted to some extent on
follow-up. It is not clear whether this signature is
broadly predictive of risk or simply represents perturb-
ation during the event. Addressing this distinction re-
quires a large prospective cohort with RNA samples
archived for follow-up assessment of adverse cardiovas-
cular events. Here, we performed Illumina microarray-
based gene expression profiling to quantify the relative
abundance of transcripts in peripheral blood that are as-
sociated with AMI and/or CAD. Further, we investigated
whether these markers are also associated prospectively
with the risk of future cardiovascular death. We show
that two axes of gene expression co-variation, each in-
cluding hundreds of transcripts related to lymphocyte
and neutrophil activity, are differentially expressed dur-
ing AMI. A distinct subset of these generate a predictor
of future cardiovascular death that replicates in two
phases of analysis and is strongly associated with sur-
vival time in the combined dataset.
Methods
Subjects
We studied 338 subjects with suspected or confirmed
CAD undergoing cardiac catheterization who were en-
rolled in the Emory Cardiovascular Biobank. The study
was approved by the institutional review boards at
Emory University and the Georgia Institute of Technol-
ogy, Atlanta, GA, USA, and was conducted in accord-
ance with the principles of the Declaration of Helsinki.
All subjects provided written informed consent. Subjects
were evaluated in two phases, the discovery phase with
175 subjects and replication phase with 163 subjects.
Coronary angiograms were scored for luminal narrowing
using a modified American Heart Association/American
College of Cardiologists classification [14]. Patients were
designated as having non-significant CAD (visible plaque
resulting in <50% luminal stenosis), or significant CAD
(at least one major epicardial vessel with ≥50% stenosis).
Subjects with congenital heart disease, severe valvular
heart disease, history of orthotopic heart transplant,
severe anemia, recent blood transfusion, active inflam-
matory diseases, or cancer were excluded. Clinical char-
acteristics and behavioral factors were obtained using
a comprehensive questionnaire and were confirmed
by electronic chart review. Risk factor prevalence was
determined by physician diagnosis and/or treatment of
hypertension, hyperlipidemia, and diabetes and detailed
medication history was obtained [15]. Prevalent myocar-
dial infarction (MI) at the time of enrollment was diag-
nosed using standard universal criteria. Quantitative
angiographic scoring was performed using the Gensini
score that quantifies CAD severity by a nonlinear pointssystem for degree of luminal narrowing. The score has
prognostic significance [16].
Clinical outcome measures
Based on their initial evaluation, patients were divided
into those with non-significant CAD, those with signifi-
cant CAD by the above criteria, those with AMI on ad-
mission, and those with a history of MI (labeled NO
CAD, CAD, AMI and OLD MI, respectively). Follow-up
evaluation was conducted by telephone interviews and
by chart review by personnel blinded to the gene expres-
sion data, between 1 and 5 years (mean 2.4 years) after
blood sampling, in order to determine all cause death,
non-fatal MI, and cardiovascular death. Records were
also linked to the Social Security Death Index and State
of Georgia records. Cardiovascular death was defined as
death attributable to an ischemic cardiovascular cause
(fatal MI, stroke, peripheral arterial disease) or sudden
death due to an unknown cause [15]. Medical records
were accessed or requested to validate all self-reported
events including MI, which was defined using standard
international criteria for diagnosis.
Gene expression profiling
Gene expression data have been deposited at the Gene
Expression Omnibus archive under accession number
[GEO:GSE49925]. Peripheral blood samples were col-
lected immediately prior to angiography and after over-
night fasting, and stored in Paxgene tubes (QIAGEN,
San Diego, CA, USA) at -80°C. Microarray analysis of
transcript abundance was performed by hybridization of
dye-labeled RNA to Illumina HT-12 bead arrays contain-
ing probes for all human reference genes. Hybridizations
for the discovery phase were performed by Expression
Analysis (Durham, NC, USA) and for the replication
phase by HudsonAlpha (Huntsville, AL, USA). Average
bead intensity values were exported from the Illumina
GenomeStudio, log base 2 transformed, and 14,343 probes
that are consistently detected above background in mul-
tiple gene expression datasets that we have analyzed
[17-19] were retained for subsequent analyses. Of these
probes, 232 were missing in the replication phase analysis
using an updated version of the Illumina HT-12 arrays,
resulting in 14,111 probes analyzed in both phases.
Two modes of data normalization were pursued in
order to confirm robustness of all conclusions [20]. The
primary analysis method reported in the main text
employed the Supervised Normalization of Microarray
(SNM) algorithm [21,22]. Secondary analyses were per-
formed by linear mixed modeling at the transcript level
[23]. All downstream analysis of variance and regres-
sions on traits was performed with JMP Genomics v5
(SAS Institute, Cary, NC, USA). Normalization was ini-
tially performed independently on the two phases to
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data were combined for meta-analysis. The variance
components attributable to body mass index (BMI), gen-
der, ethnicity, CAD status and technical plate effects are
shown in Additional file 1.
SNM was implemented in two steps in order to re-
move technical effects and adjust for biological covari-
ates. In step one, we fit CAD status (with four levels:
NO CAD, CAD, AMI and OLD MI) as the biological
variable of interest, and adjusted for BMI, gender, ethni-
city (in the discovery phase only since all individuals in
the replication phase were Caucasian) and age (in the
replication phase only, since it was not correlated with
the major components of variance in the discovery
phase). In step two, we also fit CAD status as the bio-
logical variable, but removed the technical effects of
RNA quality (bioanalyzed RNA integrity number (RIN)
number) and plate (two per phase) using the rm.adj =
TRUE option. The π0 estimate for both phases was be-
tween 60 and 70%, indicating that this proportion of the
transcripts was unaffected by presence or absence of sig-
nificant CAD status but suggesting that up to as many
as 4,500 transcripts may differ between those with and
without CAD or AMI. Code and input. csv files are
available from the authors’ website [24].
For the linear regression normalization, log2 fluores-
cence intensity measures were mean-centered by indi-
vidual and linear regression fitting RNA quality and
plate was performed, after which the residuals for each
probe were converted to standardized normal distribu-
tions (z-scores). These were then re-centered by individ-
ual by subtracting the mean z-score of all probes,
yielding the normalized gene expression measures.
Expression quantitative trait locus analysis
Whole genome genotypes for the discovery phase were
determined by Illumina OmniQuad arrays at Expression
Analysis (Durham, NC, USA), and retained where calls
were made for 95% of the individuals and Hardy-
Weinberg equilibrium observed at P > 0.001. Expression
quantitative trait locus (eQTL) analysis was performed
only on the Caucasian samples (n = 153) by linear re-
gression against the SNM normalized expression values
(similar results were observed for the alternative
normalization). Genotypes were excluded if the minor
allele frequency was less than 0.1, to avoid rare homozy-
gotes biasing the analysis, and we also required at least
two individuals in each genotype class. Only local (cis)
associations (SNPs within 250 kb of the probe) were
assessed since this analysis is underpowered to assess
distal (trans) associations, and in Additional file 2 we re-
port only the strongest association per locus since the
study is underpowered to detect multiple associations
even in the presence of reduced linkage disequilibrium.In addition, 3,651 probes known to contain common
SNPs were removed from the analysis [25], including 39
putativeeQTL.
Principal component analysis and axes of variation
Principal component analysis (PCA) was used to define
the major orthogonal components of variation across all
transcripts, using the Basic Expression Workflow routine
in JMP Genomics (SAS Institute, Cary, NC, USA). The
contributions of the aforementioned biological covariates
were assessed as a weighted sum of the proportion of
each principal component (PC) explained. ANOVA was
then used to assess whether clinical status impacts any
of the major PCs individually. In addition, we assessed
the correlation between each PC and white blood cell
(available for 96% of subjects) and neutrophil counts
(16% of subjects) as shown in Additional file 3. A sum-
mary of the workflow is provided in Additional file 4.
Since the loadings of the PC are only partially con-
served between any two studies (including the phases)
and there is no biological reason for axes of variance to
be orthogonal, we also adopted an analysis of nine con-
served axes of variation following the strategy we re-
cently defined from re-analysis of multiple peripheral
blood gene expression profiling datasets [17]. Each axis
represents strong co-variance of several hundred tran-
scripts with a correlation coefficient r > 0.7 that appear
to represent different aspects of immune function. They
are defined by an axis score that is generated as PC1 for
a set of 10 blood informative transcripts that we have
shown consistently correlate with the respective axis
[17]. Each of these axis scores explains 70% to 95% of
the variation in the set of 10 blood informative tran-
scripts, compared with just approximately 25% for any
randomly chosen set of 10 transcripts. Multiple regres-
sion of all nine axis scores on all of the transcripts was
performed for each phase, and over 5,070 probes associ-
ated with at least one axis in either phase. Cross-
matching of the list of significant associations between
the two phases showed, on average, 81% overlap, ranging
from 61% for axis 9 to 91% for axis 3. Those transcripts
that are significantly associated at the approximate
Bonferroni threshold of P < 10-5 in both phases (2,432
probes) were retained as axis-associated transcripts
(Additional file 5).
Statistical analyses
Differential gene expression between classes of subject
(AMI versus non-AMI; cardiovascular death versus re-
mainder; drug treatments) was evaluated by analysis of
variance on the normalized data. Volcano plots [23]
show the significance for each probe as the negative
logarithm of the P-value (NLP) against the magnitude of
difference (log 2 scale, 1 represents a 2-fold change).
Kim et al. Genome Medicine 2014, 6:40 Page 4 of 13
http://genomemedicine.com/content/6/5/40For survival analysis, both cohorts were pooled and
PC1 scores were categorized by outcome specific re-
ceiver operating characteristic (ROC) analyses using
Youden’s index (Sensitivity - (1 - Specificity)) [26] to
identify the threshold for 'high' and 'low' cardiovascular
death-associated PC1 scores in both cohorts separately.
The relationship between PC1 score and outcomes was
determined using the Cox proportional-hazards regres-
sion in unadjusted models and in models adjusted for
established risk factors that included age, gender, BMI,
serum creatinine, diabetes, hypertension, hyperlipidemia,
smoking, statin use, AMI and CAD (>50% luminal sten-
osis) all at baseline. The ability of the standard clinical
model for predicting adverse events was calculated using
the C-statistic before and after addition of the PC1 score.
Gene enrichment analysis was performed with the
ToppGene Suite [27], and showed a highly significant
enrichment (hypergeometric P = 4 × 10-8) for 18 genes
annotated to the set of 222 genes known to be up-
regulated in CD133+ relative to CD133- hematopoietic
stem cells in the 'Jaatinen_HSC_Dn' Molecular Signa-
tures Database (MSigDB) [28] entry. No other signifi-
cant multiple comparison-adjusted enrichments were
reported.Results
Table 1 includes the demographic and clinical character-
istics of subjects in the discovery phase (175) and repli-
cation phase (163). Of the 338 subjects, 65% were male,
the mean age was 61 years, and 70% had significant
CAD (>50% stenosis) and 18% were experiencing an
AMI. Table 1 also contrasts the MI and non-AMI sub-
jects, and shows that the AMI patients were more likely
to be male, to have diabetes, significant CAD, and higher
creatinine and Gensini scores as well as white blood cell
and, where available, neutrophil counts (n = 55).Differential expression associated with acute myocardial
infarction
Exploratory analyses indicated that as many as 4,500
transcripts may differ in abundance with respect to their
CAD status, namely NO CAD, CAD, OLD MI, or AMI.
The first five PCs explained 42% of the variation in the
discovery phase and 46% in the replication phase. Not-
ably, PC3 is significantly affected by CAD status in the
same direction in both phases, with the AMI samples
differentiated from the other three non-AMI samples
(Figure 1A,B). The remaining NO CAD, CAD, and OLD
MI groups are not significantly differentiated from one
another. Similarly, there is no relationship between tran-
script abundance and angiographic burden of CAD as
measured by the Gensini score. The absence of signifi-
cant differential gene expression among the CAD andNO CAD groups was confirmed by ANOVA contrasting
each of the three non-AMI classes (data not shown).
The differential expression in the AMI samples is
shown in the volcano plots in Figure 1C,D. The effect of
AMI is stronger in the replication phase, but the vast
majority of the genes showing highly significant differen-
tial expression in either direction in the replication
phase (red or blue spots highlighted in Figure 1D)
showed the same direction of effect in the discovery
phase (Figure 1C), indicating replication of the AMI ef-
fect. Remarkably, differential gene expression in 11 indi-
viduals who had an MI during the follow-up period for
the discovery sample also tends to be in the same direc-
tion (Figure 1E; insufficient sample size for replication
phase). Furthermore, Kiliszek et al. [13] reported 24
genes that were differentially expressed in a set of 28 pa-
tients experiencing AMI relative to controls, as well as
at 6 months follow-up, and although these genes are not
the most significant in our list, PC1 for their 24 genes
is significantly associated with AMI in our cohort (one-
tailed t-test, P = 5 × 10-5) and corresponds very closely
to the major component of AMI-associated gene ex-
pression in our study. This differential ranking of top
genes is to be expected as the most significant tran-
scripts in any particular sample will be influenced by
sampling variance.
To explore the nature of the differential expression
further, we evaluated the nine axes of variation that we
recently showed are highly conserved in peripheral
blood gene expression profiles from multiple studies in
healthy and disease cohorts [17]. Each of 2,432 tran-
script probes associated with the same axis in both
phases was classified as an axis gene. The directionality
of the average difference in transcript abundance be-
tween the AMI and non-AMI samples for each gene,
plotted by axis in Figure 2A,B, is highly concordant be-
tween the two phases. There is unambiguous downregu-
lation of genes in axis 1 and upregulation of genes in
axis 5 in AMI patients. In other studies, axis 1 is corre-
lated with lymphocyte count and axis 5 with neutrophil
count [17], and these relationships are confirmed for
the subset of samples with cell counts in this study
(Additional file 3). Neutrophil counts were not available
for most individuals, but fitting white blood cells into a
linear model absorbs the association of the axes with
AMI (Additional file 6), indicating that much of the
axis association is due to their correlation with white
blood cell counts.
eQTL analysis shows that differential expression in AMI
involves changes in cell counts and gene expression
Evidence that the high expression of genes in axis 5 is
only partially explained by neutrophilia is provided by
cross-matching of the 1,987 genes associated with axis 5
Table 1 Baseline characteristics











Age (years) 62 ± 11 67 ± 10 56 ± 10 65 ± 11 61 ± 11 0.014
Male gender (%) 218 (65) 112 (64) 106 (65) 47 (78) 171 (62) 0.015
Caucasian race (%) 331 (98) 170 (97) 163 (100) 58 (97) 273 (99) 0.19
Systolic blood pressure (mmHg) 138 ± 23 142 ± 23 133 ± 21 135 ± 23 138 ± 23 0.36
BMI (kg/m2) 30 ± 7 29 ± 6 31 ± 8 29.6 ± 6.8 30.2 ± 7.0 0.53
Serum creatinine (mg/dl) 1.3 ± 1.1 1.3 ± 1.4 1.2 ± 0.7 1.6 ± 2.2 1.2 ± 0.7 0.009
Acute MI (%) 60 (18) 37 (21) 23 (14) - - -
Old MI (%) 109 (32) 61 (35) 48 (30) 13 (22) 96 (35) 0.060
Current smoking (%) 73 (22) 34 (19) 39 (24) 8 (14) 65 (24) 0.09
Diabetes (%) 120 (36) 65 (37) 55 (34) 29 (48) 91 (33) 0.024
Hypertension (%) 258 (77) 142 (81) 116 (72) 46 (77) 212 (77) 0.98
Dyslipidemia (%) 263 (78) 133 (79) 102 (77) 47 (78) 216 (78) 0.95
Chronic heart failure (%) 76 (23) 41 (24) 35 (21) 15 (25) 61 (22) 0.61
LVEF (%) 54 ± 11 54 ± 11 54 ± 11 51 ± 11 54 ± 11 0.06
HDL (mg/dl) 43 ± 15 44 ± 14 41 ± 16 38 ± 14 44 ± 15 0.014
LDL (mg/dl) 92 ± 37 91 ± 36 94 ± 38 85 ± 33 94 ± 37 0.13
Triglyceride (mg/dl) 159 ± 115 150 ± 93 170 ± 137 154 ± 107 160 ± 117 0.73
Total cholesterol (mg/dl) 166 ± 45 164 ± 42 169 ± 48 153 ± 35 169 ± 47 0.02
History of CABG (%) 73 (21) 42 (24) 31 (19) 13 (22) 60 (22) 0.99
Gensini score 35 ± 54 38 ± 57 31 ± 55 48 ± 54 32 ± 54 0.046
Aspirin use (%) 83 131 (81) 131 (84) 48 (89) 214 (82) 0.2
Beta blocker use (%) 213 (67) 107 (67) 106 (67) 45 (82) 168 (64) 0.012
Clopidogrel use (%) 171 (55) 91 (56) 80 (53) 34 (64) 137 (53) 0.13
ACE-inh/ARB use (%) 192 (61) 100 (62) 92 (61) 35 (67) 157 (60) 0.35
Statin use (%) 244 (78) 129 (80) 115 (76) 44 (83) 200 (77) 0.33
>50% stenosis (in any major epicardial artery (%) 235 (70) 133 (76) 102 (64) 59 (93) 176 (64) <0.001
P-value denotes differences between those with and without AMI. Abbreviations: ACE-inh/ARB angiotensin converting enzyme inhibitor or angiotensin receptor
blockers, BMI body mass index, CABG coronary artery bypass graft, HDL high-density lipoprotein, LDL low-density lipoprotein, LVEF left ventricular ejection
fraction, MI myocardial infarction.
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expression profiles of distinct blood types from the
Immunological Gene Consortium [29,30]. This indicates
that 45% of 2,469 genes known to be neutrophil-
enriched are associated with axis 5 in this study, and
55% of the axis 5 genes are neutrophil-enriched. The fact
that the overlap is only partial suggests that neutrophil
abundance is not the only explanation for the differential
expression. Similarly, reduced lymphocyte abundance
does not solely explain the low axis 1 scores in AMI pa-
tients, since only 44% of 1,746 axis 1 genes (at 5% FDR)
are known to strongly associate with T-lymphocyte
abundance. Furthermore, axes 8 and 9 are also enriched
for genes involved in aspects of T-cell signaling, while
axis 3 has an excess of genes annotated to B-cell signal-
ing. None of these axes are associated with AMI. These
results imply that differential gene expression in AMIpatients is partly attributable to elevation of the ratio of
neutrophils to lymphocytes, and partly to differential
gene expression within these cell types.
To confirm this, we compared genotypic effects on
gene expression between AMI and non-AMI samples in
the discovery phase. A genome-wide association study
measuring the effects of locally acting common poly-
morphisms on the abundance of each of the 14,343 tran-
scripts was performed. Only the 153 Caucasian samples
were included to prevent possible ethnicity-associated
influences, and only SNPs with a minor allele frequency
greater than 0.1 and located within 250 kb of the probe
were assessed, also excluding probes known to contain
SNPs to avoid hybridization artifacts [25]. Local genetic
regulation of transcript abundance was detected for 355
probes representing 334 genes at P < 10-5, with a q-value
FDR of 1%. On average, each lead eSNP (the strongest
ppA Discovery Phase =0.0025 B Replication Phase =0.0202
C Discovery Phase D Replication Phase E Discovery Phase Follow-up
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Figure 1 Differential expression according to coronary artery disease status. (A,B) PC3 scores by disease classification in the two phases of
transcriptome profiling. P-values from ANOVA with three degrees of freedom for group effect, implying replicated differential expression between
individuals presenting with AMI and those with NO CAD, CAD and OLD MI, which are not consistently divergent. (C,D) Volcano plots of
significance against difference in expression in log2 units of SNM-normalized data with genes upregulated in patients with AMI to the left, and
genes downregulated in AMI to the right. Colored transcripts are significant at P < 10-5 in phase 2. Almost all of these are differentially expressed
in the same direction in phase 1, which, however, showed much less evidence for significant differential expression in the total sample (possibly
reflecting lower technical quality, or unknown covariates biasing against the AMI association). (E) Volcano plot of differential expression between
non-AMI individuals who have had an MI on follow-up (n = 11) and the remainder, all in phase 1.
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the associated transcript of 0.46, with a range from 0.27
to 0.90.
In order to evaluate whether AMI status influences
local genetic effects on gene expression, we re-
performed the eQTL analysis on just the 120 no-AMI
Caucasian samples. This resulted in the reduction in sig-
nificance of 154 associations (by at least 0.5 NLP value)
as expected due to the reduced power in a smaller sam-
ple, but also led to the increase in significance of 76
associations, including detection of 45 novel associa-
tions, at P < 10-5 (Figure 3B). Additional file 2 lists the
location, probe and SNP identity, and the Pearson cor-
relation and NLP value for all 303 eSNPs detected at
NLP >5 (P < 10-5) in the non- AMI sample, compared
with the all Caucasian associations. Of the cases with
increased genotype effects in the non-AMI sample, 72%
show a significant interaction effect between genotype
and AMI status. In each case they show a non-significant
relationship between genotype and gene expression in the
AMI samples where a highly significant one exists in the
non-AMI samples (Figure 3D). By contrast, only 12% ofthe cases of reduced significance in the non-AMI samples
showed an interaction effect, each with only a mild in-
crease of AMI status on the genotypic effect (Figure 3E).
This result, that AMI reduces the genetic regulation of
expression of a subset of genes, could simply be ex-
plained if the eSNP effect is predominately observed in
lymphocytes and/or monocytes, so is diluted out in the
AMI samples where neutrophils are more prevalent. To
exclude this explanation, we removed an equivalent
number of non-AMI high axis 5 samples from the total
discovery phase dataset, and re-performed the eSNP
evaluations. As expected, significance was reduced for
183 genes due to the loss of power, but only 36 cases of
increased significance below the P < 10-5 threshold were
observed. Consequently, the altered genotype effect is
not simply a function of high axis 5 scores, but more
often reflects an AMI-specific loss of influence on gene
expression. To our knowledge, a study-specific disease-
by-genotype interaction effect on local regulation of
gene expression has only previously been reported for
the effect of Plasmodium parasite load in infants with

































































































Figure 2 Replicated association of axes of variation with myocardial infarction. Each gene that is correlated with one of the nine axes in
both phases is plotted, showing the mean difference between individuals with and without AMI (higher expression in AMI producing negative
values). The overall relationship of the axes with AMI status is highly replicated, notably showing downregulation of axis 1 and upregulation of
axis 5. The difference between the studies in axis 2 is readily explained because this axis is associated with BMI, which is elevated in the
replication phase sample.
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In the combined cohort, there were 31 (9.5%) cardiovas-
cular deaths during follow-up of 326 patients (12 pa-
tients, 3.6% were no longer available). In the discovery
phase sample, analysis of variance contrasting 23 indi-
viduals experiencing cardiovascular death during follow-
up with the remaining survivors revealed 244 probes in
238 genes that were significantly differentially expressed
at P < 0.01. The first PC of these probes explains 23.3%
of their variance in the joint sample of 338 individuals.
Two-way hierarchical clustering of these transcripts re-
vealed three groups of individuals showing co-expression
of these transcripts (Additional file 7). PC1 of these genes
is predictive of cardiovascular death with an area under
the ROC curve (AUC) of 0.80. This result was then
verified in the replication phase sample in which eight
patients experienced incident cardiovascular death, produ-
cing an AUC of 0.77. After combining the two datasets,
hierarchical clustering recapitulates the clustering and a
joint AUC of 0.78 was obtained (Figure 4B). Of the 219
subjects in the blue or orange clusters (Figure 4A), 28
(12.7%) died during follow-up compared with just 3 (2.5%)
of the 119 subjects in the red cluster (2.5%), LRT χ2 =
17.8, P = 0.0006.
The best cutoff for the transcriptional PC1 score of the
238 differentially expressed genes in predicting cardiovas-
cular death was determined to be -3.5 non-dimensional
units using Youden’s index [26]. Kaplan-Meier survival
analysis demonstrates a highly significant difference in
survival between the 97 individuals with a PC1 score
below -3.5 and the remaining 71% of subjects with PC1
score above -3.5 (P = <10-7; Figure 4D).
Univariate predictors of cardiovascular death indicated
in Table 2 were age, low density lipoprotein, totalcholesterol, serum creatinine, AMI, white blood cell
count, presence of significant CAD >50%, left ventricular
ejection fraction, and PC1 score, with hypertension
trending towards significance. Multivariate cox propor-
tional hazard analysis including univariate predictors
with P < 0.20 reveals age, serum creatinine, and PC1
score < -3.5 as independent predictors of cardiovascular
death during follow-up, where the hazard ratio for the
PC1 score indicates a more than eight-fold increased risk
of death. Furthermore, discrimination analysis shows
that the addition of PC1 score to a baseline model com-
prising all of the terms listed in Table 2 was associated
with improvement in the C-statistic (AUC 0.82 to 0.91,
P = 0.03).
Additional file 8 lists the genes that are present in the
signature. Diverse functions are represented, notably
several genes involved in gylcerophospholipid metabol-
ism and sphingomyelin-mediated signaling (PRKCH),
thrombosis (CD59), leukocyte recruitment (CD63), spli-
cing, and PI3K-Akt signaling, also with a highly signifi-
cant enrichment for 18 genes known to be upregulated
in CD133+ hematopoietic stem cells. Since half of these
transcripts are positively and half negatively associated
with PC1, it is unlikely that they simply report progeni-
tor cell activity.
The differential expression associated with incident
cardiovascular death appears to involve similar compo-
nents of variation as the AMI-associated genes, since
the PC1 score is correlated with those of axes 1 and 5.
Even though the identities of most of the highly signifi-
cant genes are distinct from the AMI-associated genes,
22 of the 230 PC1 genes are associated with axis 1 at
P < 10-5. Figure 5 compares volcano plots between the
two phases (Figure 5A,B), using the SNM normalization
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Figure 3 eQTL analyses. (A-C) Plots of significance (NLP) of local eSNPs with a transcript probe located within 250 kb of the SNP, contrasting
the full Caucasian sample in the discovery phase with the same sample minus all individuals experiencing an MI. (A) The full range; (B) eSNPs in
the range 5 < NLP < 15. Colored points differ between the full and non-AMI samples by at least 0.5 NLP units, red indicating higher significance in
the smaller sample, and blue higher significance in the full sample. (C) The same analysis as (B) but missing 39 individuals with the highest axis 5
scores who were not experiencing an MI. Numbers show the number of eSNPs in the red and blue categories across the full range of NLP >3.
(D,E) Representative plots of transcript abundance by genotype, colored with respect to MI status (red experiencing an MI, blue no-MI). Lines
show the slope of the two classes, indicating an interaction effect in (D) but no interaction effect in (E).
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http://genomemedicine.com/content/6/5/40strategy (red and blue transcripts in all panels in
Figure 5 are colored with respect to the cardiac death
association in the discovery phase). The vast majority
of genes upregulated in individuals in the discovery
phase who subsequently died of a cardiovascular event
are also upregulated in the replication phase individuals
who have died, as well as in the patients experiencing
an AMI (Figure 5D). Furthermore, when we remove the
37 patients from the discovery phase who were experi-
encing an AMI, and compute the association with sub-
sequent death, these genes all remain upregulated
(Figure 5E). Similarly, the downregulated genes in pa-
tients experiencing an AMI and who subsequently
experienced cardiovascular death all strongly tend to
co-vary in the same direction. As a negative control for
these comparisons, Figure 5C shows that there is no
bias of the cardiovascular death-associated genes with
respect to CAD status. It is also noteworthy that the
sign of differential expression in individuals who expe-
rienced a follow-up MI without death tends to be in
the same direction as well (Figure 5F). Similar results
using the linear regression normalization are shown in
Additional file 9.Relationship between gene expression, subject
characteristics and medication use
Ethnicity and BMI contribute to differences in transcript
abundance (Additional file 1) as observed in our other
cohorts [17,19]. We also assessed whether cardiovascular
medications are associated with gene expression. One-
way ANOVA on statins, angiotensin antagonists, beta
blockers, clopidogrel, or aspirin usage did not demon-
strate noteworthy drug-specific enrichment for gene ex-
pression. In either phase, we did observe significant
association between axis scores and usage of clopidogrel
or beta blockers, but these effects did not replicate in
both phases (Table 2).
Discussion
Our two novel findings relating to the relationship be-
tween gene expression variation and clinical syndromes
associated with CAD are 1) demonstration of a clear
transcriptomic signature of AMI that is indicative of a
pro-inflammatory response, and 2) that a subset of this
axis of peripheral blood gene expression is likely associ-
ated with the risk of cardiovascular death during
medium-term follow-up [32]. Importantly, the PC1 gene
Figure 4 Gene expression predictor of incident cardiovascular death. (A) Two-way hierarchical plot of normalized transcript abundance
(columns) by subjects (rows), highlighting the three deepest clusters. The column to the left illustrate subjects with cardiovascular death during
follow-up: note the over-representation in the blue cluster and under-representation in the red one. (B) ROC for the sensitivity of PC1 of the 238
probe (230 gene) signature of cardiovascular death in the joint analysis. (C) Projection of hierarchical clusters on first two PCs. (D) Kaplan-Meier
survival curve contrasting individuals in the bottom 29% of PC1 (blue curve; PC1 < -3.5), which includes 97 subjects (all 51 of the blue cluster and
46 of the orange cluster), and the remaining 71% (red curve; n = 240, PC1 > -3.5).
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http://genomemedicine.com/content/6/5/40score added predictive value to standard risk factors,
with a hazard ratio over 8 in a multivariate model, and
demonstrated improvement in the standard C-statistic.
Moreover, our key results are based on replication in
two independent phases of genomic data acquisition in
the Emory Cardiovascular Biobank, and have been vali-
dated using two parallel modes of data normalization.
Other findings are a lack of association between the
transcriptome and the presence and severity of CAD,
occurrence of previous MI, or with cardiovascular
medication use.
Gene expression associated with AMI and with incident
cardiovascular death
We found an unambiguous association between a pro-
inflammatory gene expression profile and presentation
with AMI. The fact that samples were drawn within 2 to
24 hours after AMI, and that the two associated axes
of variation (axis 5 and axis 1) are heavily enriched
for upregulation of neutrophil and downregulation ofT-lymphocyte gene activity, respectively, suggest that
this pattern of gene expression may have been the result
of AMI rather than its cause. However, these observa-
tions may not be entirely explained by neutrophilia that
accompanies AMI [33,34]. First, not all neutrophil- and
T-lymphocyte-enriched transcripts were altered to the
same extent. Thus, in addition to modification of the ra-
tio of cell types, there is differential activation of the co-
regulated innate and adaptive gene functions. Secondly,
20% of the eQTL effects are stronger in subjects without
AMI than in those with AMI, indicating altered genetic
regulation of gene expression. Thus, we conclude that
AMI is associated not just with an increase in neutrophil
activity, but also with an alteration of gene activity in
both neutrophils and lymphoctyes.
Our results suggest that there may be a specific subset
of leukocyte gene activity that is associated with a par-
ticularly high risk of death among individuals with CAD.
Our current sample is too small to evaluate whether
genotypic differences contribute to this risk category.
Table 2 Univariate and multivariate predictors of
cardiovascular death
Cardiovascular death (N = 31)
Univariate Multivariate
β P-value HR P-value
Age 0.05 0.002 1.07 0.007
BMI -0.04 0.13 1.01 0.789
Male gender -0.23 0.52 - -
Diabetes 0.59 0.10 0.69 0.49
Hypertension 1.43 0.05 1.89 0.44
Smoking 0.39 0.33 - -
Prior MI -0.56 0.11 1.53 0.49
Statin use -0.71 0.18 0.31 0.14
Aspirin use 0.19 0.66 - -
LDL cholesterol -0.01 0.03 1.002 0.91
Total cholesterol -0.01 0.01 0.98 0.32
Serum creatinine 0.31 <0.001 1.28 0.008
Acute MI 0.48 0.29 - -
White blood cell count 0.13 0.01 1.19 0.51
CAD >50% 0.97 0.04 2.68 0.15
LVEF -0.03 0.01 0.96 0.08
PC1 score <3.5 2.08 <0.001 8.53 <0.001
Significant predictors are highlighted in bold. Abbreviations: BMI body mass
index, HR hazard ratio, LDL low-density lipoprotein, LVEF left ventricular
ejection fraction.
Kim et al. Genome Medicine 2014, 6:40 Page 10 of 13
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but the finding that genotypes affect response to a car-
diac event also raises the question of whether enrich-
ment with certain genotypes affects an individual’s
physiological response to AMI. Just as with genome-
wide association studies, it will likely take joint gene ex-
pression and whole genome genotype studies of tens of
thousands of individuals with CAD to identify robust
genomic biomarkers of risk for adverse events. This sig-
nature is, to some extent, co-regulated by whatever pro-
cesses result in coordinate expression of genes in axis 1
and axis 5, but appears to involve additional coordinated
regulation of transcription of a subset of genes with di-
verse molecular functions. Although the cardiovascular
death signature appears to be related to that of AMI, it
is only a subset of it, since comparison of Figure 5A,B
with Figure 5D indicates that the transcripts most
strongly associated with death in both phases are only
weakly associated with AMI. Both the AMI and cardio-
vascular death associations are in the same direction in
individuals who experienced a follow-up non-lethal MI,
further indicating that there is some commonality to the
cellular and transcriptional bases to the gene expression-
based risk of adverse cardiovascular events.In order for this profile to be incorporated into clinical
practice, it would be favorable to ascertain a mechanism
that explains the association between gene expression and
risk of death. Possibilities include potential for plaque vul-
nerability, arrhythmogenesis, rapid occlusive thrombosis,
mediation or repair of vessel walls, and regulation of signal-
ing between the vascular endothelium and circulating
blood cells. Understanding of the mechanism may lead
to development of new therapeutic targets and subsequent
interventions. The combination of traditional risk factors,
genotypic risk from genome-wide association study vari-
ants [11,12], emerging biochemical predictors of cardiovas-
cular death [15], and peripheral blood gene expression
profiling nevertheless provides a framework for identi-
fying a population at extraordinarily high risk for ad-
verse outcomes, and for the aggressive management of
cardiovascular disease that is personalized, predictive
and participatory, with the hope that it may also lead to
preventive risk reduction [35].
Lack of gene expression association with coronary artery
disease
Several peripheral blood microarray studies have re-
ported transcriptomic signatures associated with the
presence of underlying CAD. The CardioDx Corus®CAD
signature [9,10], which was identified in a sample of over
1,000 individuals, was not replicated in our cohort. This
23 gene quantitative RT-PCR assay is reported to im-
prove the predictive accuracy of traditional risk factors
for atherosclerosis in a sex-specific manner in non-
diabetics and was validated in the multicenter PREDICT
trial. It includes genes that capture activity in a small
number of biochemical pathways and/or represent the
abundance of neutrophils. The most likely reason for
lack of our ability to replicate their findings is confound-
ing clinical attributes, given that the majority of our
cohort already have CAD and are receiving diverse
pharmacological treatments, as a result of which the
control healthy adult sample is relatively small.
We also failed to observe a strong relationship be-
tween gene expression and the use of aspirin, statins,
angiotensin antagonists, beta blockers, or clopidogrel.
Although clopidogrel showed a significant association
for several hundred genes in the discovery phase, these
did not replicate in the replication phase. It is likely that
the very high covariance of gene expression into axes of
coordinated gene expression that explain over half of the
variance among individuals readily induces correlations
that do not replicate. These axes are correlated with
genetic, environmental and unknown sub-clinical mea-
sures in a multivariate manner, and may have high false
positive rates in relatively small samples. These consider-
ations underscore the relevance of the observed replica-
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Figure 5 Volcano plots contrasting differential expression with respect to CAD status, AMI, or incident cardiovascular death. Data were
transformed by the SNM procedure (see Additional file 9 for similar analysis of standard normalized data). (A) Cardiovascular death versus
survivors in the discovery phase, where shaded points indicate transcripts that are differentially expressed at NLP >2.7 (5% FDR). (B) Replication of
cardiovascular death direction of effect in the replication phase. (C) No CAD versus CAD, showing absence of overlap with AMI or cardiovascular
death in direction of effects. (D) AMI versus no-AMI in the discovery phase, showing similarity of direction of differential expression relative to
(A). (E) Cardiovascular death versus survivors; same as (A) but after removing all individuals who were experiencing an AMI. (F) Individuals who
experienced an AMI after enrolment versus not at all, also showing the cardiac death signature is in the same direction for predicting heart attack
in general.
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nature with cardiovascular death needs to be replicated
in an independent prospective cohort because only 31 of
the 338 subjects reported here have suffered a cardiovas-
cular death. A strength of our study is that all of our
findings replicate in two phases, and we have performed
careful normalization using two parallel modes of ana-
lysis to confirm the results and relate them to our prior
evaluation of the axes of variation in human peripheral
blood. Future research will need to carefully measure
complete blood counts, as these were not available for
the AMI patients in this study and the confounding of
neutrophilia with the inflammatory and cardiovascular
death signatures was inferred from a subset of the data
and other studies. Longitudinal analyses of gene expres-
sion will also assist in interpretation of the effect of AMI
on future risk, and possibly also evaluation of whether
lifestyle changes that reduce CAD risk also alter the per-
ipheral gene expression profiles in a favorable direction.
Conclusion
A signature of gene expression related to inflammation
and altered T-cell signaling correlates with incident AMIand a subset of these associate with risk of cardiovascu-
lar death. The core result evaluated across both phases
of the study produces a combined AUC of 0.78 and im-
proves the C-statistic of risk classification when evalu-
ated alongside 12 clinical measures. If independently
validated, a peripheral blood transcript abundance test
has potential, in conjunction with measures of choles-
terol, serum creatinine, and white blood cell counts, to
generate a significant predictor of risk of cardiovascular
death in patients with CAD. The signature appears to be
independent of the influence of conventional CAD med-
ications. We envisage a tiered approach to genomic
medicine for CAD risk assessment that incorporates
traditional risk factors, biochemical biomarkers, geno-
typic risk scores, and gene expression.Additional files
Additional file 1: Figure S1. Variance components of gene expression.
The histograms show the weighted average contribution of each
variance component to the variation in the first five principal
components of SNM normalized gene expression in the discovery and
replication phases. BMI3 is a three-level categorization of BMI (obese,
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http://genomemedicine.com/content/6/5/40BMI >30, over-weight 25 < BMI < 30, normal, BMI <25). CAD status is the
four levels described in the text. Plate effects were removed in the SNM
model. Residual is unexplained variance.
Additional file 2: Table S1. List of eSNPs at NLP >5 comparing
Caucasian and no AMI.
Additional file 3: Table S2. Association of gene expression with cell
counts.
Additional file 4: Figure S2. Schematic of the gene expression
profiling analysis.
Additional file 5: Table S3. List of probes associated with axes.
Additional file 6: Table S4. Association of white blood cells with axes.
Additional file 7: Figure S3. Survival analysis in both phases. (A, B)
Hierarchical clustering was performed independently for the discovery
(A) and replication (B) phases with the 238 probe (230 gene) signature
of cardiovascular death. Red, blue and orange clusters are as in Figure 4,
and horizontal notches beside each heat map show individuals who
have died due to a cardiovascular event during the follow-up period.
(C, D) Corresponding ROC curves for PC1 as a function of cardiovascular
death in both phases independently. Note that (B) and (D) use the same
genes in the replication phase that were discovered in the first phase.
Additional file 8: Table S5. List of genes associated with cardiovascular
disease.
Additional file 9: Figure S4. Volcano plots by alternate normalization.
Volcano plots as in Figure 5, but following linear modeling to remove
technical effects (RNA quality and batch) from z-scores. The plots are
narrower than with the SNM normalization because this mode of
normalization also equilibrates the variance, which makes the analysis at
the level of relative rank of gene expression rather than fold-change.
Nevertheless, the key results are concordant between the two strategies.
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